Related Experiment Videos
[Therapy problems in chronic recurrent vaginal mycosis].
1Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum der Humboldt-Universität zu Berlin, Campus Charité Mitte.
Therapeutische Umschau. Revue Therapeutique
|October 9, 2002
Summary
Vulvovaginal candidiasis, a common infection, often requires systemic therapy for chronic cases. Effective treatment involves identifying the fungal pathogen and addressing reinfection sources with a multi-step approach.
Area of Science:
- Mycology
- Infectious Diseases
- Dermatology
Context:
- Vulvovaginal candidiasis (VVC) is a prevalent infection, with acute forms typically responding to topical antifungals.
- Chronic VVC presents significant therapeutic challenges, often necessitating systemic treatment.
- Recurrent infections underscore the need for comprehensive management strategies.
Purpose:
- To outline an effective therapeutic strategy for chronic vulvovaginal candidiasis.
- To emphasize the importance of pathogen identification and addressing sources of reinfection.
- To propose a multi-pronged treatment regimen for refractory VVC cases.
Summary:
- Chronic VVC management requires identifying the causative fungal species, as not all respond to standard azoles like fluconazole or itraconazole.
- A three-pronged approach is recommended: orointestinal fungal decontamination, systemic antifungal therapy tailored to the pathogen, and topical treatment with ciclopiroxolamine.
- Addressing endogenous reservoirs (oral cavity, gut) and exogenous reinfection sources (sexual partners) is crucial for successful treatment outcomes.
Impact:
- This approach aims to improve treatment efficacy for chronic and recurrent vulvovaginal candidiasis.
- Accurate diagnosis and targeted therapy can reduce treatment failures and patient morbidity.
- Optimized management strategies can lead to better quality of life for individuals suffering from persistent VVC.